MedTrace Logo

Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction

NCT05849766 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-10-16

No results posted yet for this study

Summary

A significant reduction in the incidence of CV death or hospitalization for HF has been observed in randomized trials investigating the CV benefit of Dapagliflozin. Mechanistic investigations are required to interpret the positive clinical effects of Dapagliflozin on heart structure and valvular regurgitation.

Conditions

  • Dilated Cardiomyopathy

Interventions

DRUG

Dapagliflozin Farxiga®

Dapagliflozin 10 mg once daily

DRUG

Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®

Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily

Sponsors & Collaborators

  • National Heart Institute, Egypt

    collaborator OTHER_GOV

  • University of Florida

    collaborator OTHER

  • October 6 University

    lead OTHER

Principal Investigators

  • Ahmed Essam Abou Warda · October 6 University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2024-05-01
Completion
2024-09-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05849766 on ClinicalTrials.gov